Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.
Monoclonal antibodies specific for Yersinia pestis V antigen and F1 antigen, administered singly or in combination, protected mice in models of bubonic and pneumonic plague. Antibodies showed synergy when administered prophylactically and as a therapy 48 h postinfection. Monoclonal antibodies therefore have potential as a treatment for plague.
Hill
Jim
J
Defence Science and Technology Laboratory, Porton Down, Wiltshire SP4 OJQ, United Kingdom. jhill@dstl.gov.uk
Copse
Catherine
C
Leary
Sophie
S
Stagg
Anthony J
AJ
Williamson
E Diane
ED
Titball
Richard W
RW
D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D010930:Plague / Q000517:prevention & control* / Q000628:therapy*; D052899:Pore Forming Cytotoxic Proteins; D015010:Yersinia pestis / Q000276:immunology* / Q000472:pathogenicity
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C043908:LcrV protein, Yersinia; D052899:Pore Forming Cytotoxic Proteins; C086725:caf1 protein, Yersinia pestis